Plasma exosomes impair microglial degradation of α-synuclein through V-ATPase subunit V1G1

Yunna Li1,2, Yiming Wang1, Liang Kou1

  • 1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Insights

Parkinson's disease exosomes impair lysosomal function by reducing V1G1 expression, leading to alpha-synuclein accumulation. Overexpressing V1G1 offers neuroprotection in Parkinson's disease models.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Microglia are key brain phagocytes involved in neuroinflammation and alpha-synuclein (α-syn) pathology.
  • Parkinson's disease exosomes (PD-exo) are known to promote α-syn aggregation and inflammation in microglia.
  • The precise mechanism by which PD-exo affects α-syn degradation remains unclear.

Purpose of the Study:

  • To investigate the mechanism by which PD-exosomes influence α-syn degradation in microglia.
  • To determine the role of V1G1 in PD-exosome-induced α-syn accumulation.
  • To evaluate the therapeutic potential of V1G1 in a Parkinson's disease mouse model.

Main Methods:

  • Exosomes were isolated from PD patient plasma and injected into mouse brains.
  • Lysosomal function, including pH and enzyme activity, was assessed in microglia.
  • Expression levels of key proteins (V1G1, LAMP1, α-syn) were analyzed using molecular biology techniques.
  • A Parkinson's disease mouse model was utilized to assess neuroprotection via V1G1 overexpression.

Main Results:

  • PD-exosomes decreased V1G1 expression, impairing lysosomal acidification and function.
  • This lysosomal dysfunction led to α-syn accumulation and impaired protein degradation.
  • V1G1 overexpression demonstrated neuroprotective effects in a mouse model of Parkinson's disease.

Conclusions:

  • Dysfunctional V-type ATPase, specifically V1G1, is implicated in Parkinson's disease pathogenesis.
  • Targeting V1G1 may offer a novel therapeutic strategy for Parkinson's disease.
  • V1G1 overexpression protects against neurodegeneration in an MPTP-induced Parkinson's disease model.